p16基因结构及表达异常与非小细胞肺癌的关系

目的　探讨p16基因结构及表达异常与非小细胞肺癌临床病理因素的相关性。方法　利用免疫组化、PCR -SSCP方法检测了p16基因的表达水平及第 2外显子突变 ,并将以上结果与 5 2例非小细胞肺癌 (NSCLC)临床病理因素进行相关性研究。结果　p16基因第 2外显子缺失 /突变率为 2 3 1% (12 /5 2 ) ,p16蛋白丢失率为 5 3 8% (2 8/5 2 ) ,基因的缺失和蛋白的丢失与肺癌的转移和分期有关。结论　p16基因突变及表达异常可能在NSCLC的发生、发展中起重要作用 ,检测该基因可作为临床诊断及预后评估指标。

ABNORMALITY OF P16 GENE AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE IN NON SMALL CELL LUNG CANCER

Objective To explore the mutation and down-expression of p16 gene in human non-small cell lung cancer (NSCLC) and its clinicopathological significance. Methods Immunohistochemistry and PCR-SSCP were uesd in the study to detect the relationship between the p16 gene mutation/ down-expression and its clinicopathological significance in 52 cases of non-small cell lung cancer (NSCLC), which were proved by pathology. Result Total rate of mutation/and deletion in exon2 was 23.1% (12/52), and p16 protein loss rate was 53.8% (28/52) in lung cancer. p16 gene mutation and protein down-expression occurred in NSCLC and were related to metastasis and progressive stage. Conclusion p16 gene mutation/down-expression may play an important role in the pathogenesis and clinicopathological significance of lung cancer and can be considered as a predicting marker of prognosis.